Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

ANAB – AnaptysBio Inc

Float Short %

37.37

Margin Of Safety %

Put/Call OI Ratio

1.03

EPS Next Q Diff

0.58

EPS Last/This Y

0.32

EPS This/Next Y

-0.49

Price

20.21

Target Price

49.55

Analyst Recom

1.33

Performance Q

-2.51

Relative Volume

0.44

Beta

-0.16

Ticker: ANAB




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-25ANAB26.950.140.141490
2025-07-28ANAB26.590.140.381491
2025-07-29ANAB26.170.143.301498
2025-07-30ANAB24.940.200.101581
2025-07-31ANAB24.520.190.881675
2025-08-01ANAB24.70.190.001675
2025-08-04ANAB24.180.190.081670
2025-08-05ANAB23.670.190.001673
2025-08-06ANAB22.540.191.331683
2025-08-07ANAB20.360.2014.131703
2025-08-08ANAB21.020.262.281789
2025-08-11ANAB19.820.492.002442
2025-08-12ANAB20.110.460.682426
2025-08-13ANAB20.740.460.332460
2025-08-14ANAB19.980.460.532471
2025-08-15ANAB20.130.462.502462
2025-08-18ANAB20.010.570.451550
2025-08-19ANAB19.780.573.161596
2025-08-20ANAB20.190.930.052265
2025-08-21ANAB20.360.902.062309
2025-08-22ANAB20.21.03999.992811
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-25ANAB26.949.6-32.2-5.42
2025-07-28ANAB26.649.6-30.6-5.54
2025-07-29ANAB26.227.5-30.1-5.54
2025-07-30ANAB24.987.5-23.3-5.54
2025-07-31ANAB24.557.5-29.1-5.54
2025-08-01ANAB24.697.5-33.9-5.54
2025-08-04ANAB24.237.5-29.0-5.54
2025-08-05ANAB23.697.5-28.2-5.54
2025-08-06ANAB22.537.5-22.6-5.54
2025-08-07ANAB20.377.5-11.7-5.54
2025-08-08ANAB21.037.5-54.5-5.54
2025-08-11ANAB19.98-37.7-13.2-5.54
2025-08-12ANAB20.07-30.2-42.4-4.72
2025-08-13ANAB20.72-30.2-47.1-4.72
2025-08-14ANAB19.95-30.2-20.2-4.72
2025-08-15ANAB20.13-30.2-27.3-4.80
2025-08-18ANAB20.02-36.9-25.1-4.80
2025-08-19ANAB19.79-36.9-24.3-4.80
2025-08-20ANAB20.19-36.9-29.2-4.80
2025-08-21ANAB20.36-36.9-27.6-4.80
2025-08-22ANAB20.21-36.9-24.8-4.80
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-25ANAB-0.9122.1335.48
2025-07-28ANAB-0.9122.2635.48
2025-07-29ANAB-0.9122.2635.48
2025-07-30ANAB-0.9122.2635.48
2025-07-31ANAB-0.9122.2635.48
2025-08-01ANAB-0.9122.2635.48
2025-08-04ANAB-0.9123.4235.48
2025-08-05ANAB-0.9123.4235.48
2025-08-06ANAB-0.9123.4235.48
2025-08-07ANAB-0.9123.4235.48
2025-08-08ANAB-0.9123.4235.48
2025-08-11ANAB-0.9527.8737.30
2025-08-12ANAB-1.2927.8738.02
2025-08-13ANAB-1.2927.8738.02
2025-08-14ANAB-1.2927.8738.02
2025-08-15ANAB-1.2927.8738.02
2025-08-18ANAB-1.29-14.0138.02
2025-08-19ANAB-1.29-14.0137.37
2025-08-20ANAB-1.52-14.0137.37
2025-08-21ANAB-1.52-14.0137.37
2025-08-22ANAB-1.52-14.0137.37
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-1.34

Avg. EPS Est. Current Quarter

-1.56

Avg. EPS Est. Next Quarter

-0.76

Insider Transactions

-1.52

Institutional Transactions

-14.01

Beta

-0.16

Average Sales Estimate Current Quarter

16

Average Sales Estimate Next Quarter

44

Fair Value

Quality Score

52

Growth Score

37

Sentiment Score

21

Actual DrawDown %

51.1

Max Drawdown 5-Year %

-69.3

Target Price

49.55

P/E

Forward P/E

PEG

P/S

4.6

P/B

P/Free Cash Flow

EPS

-4.48

Average EPS Est. Cur. Y​

-4.8

EPS Next Y. (Est.)

-5.29

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-107.66

Relative Volume

0.44

Return on Equity vs Sector %

271.7

Return on Equity vs Industry %

284.6

EPS 1 7Days Diff

0.7

EPS 1 30Days Diff

0.62

EBIT Estimation

-24.8
AnaptysBio, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 136
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
stock quote shares ANAB – AnaptysBio Inc Stock Price stock today
news today ANAB – AnaptysBio Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch ANAB – AnaptysBio Inc yahoo finance google finance
stock history ANAB – AnaptysBio Inc invest stock market
stock prices ANAB premarket after hours
ticker ANAB fair value insiders trading